Novel SMAC Mimetics for Targeted, Resistant Cancer Treatment
Smac Mimetics for Treatment of Cancer, Process for Preparation and Pharmaceutical Composition Thereof
Tags: CSIR Labs, India, Healthcare & Lifesciences
CSIR-Central Drug Research Institute [CSIR-CDRI]: This technology involves the development of novel SMAC mimetic peptidomimetics for the treatment of proliferative diseases, including cancer. These mimetics incorporate an unnatural amino acid that ensures favorable trans amide bond geometry for binding to target proteins. The SMAC mimetics effectively bind to the BIR-2 and BIR-3 domains of XIAP, showing high anti-proliferative activity against various cancer cell lines, including those resistant to chemotherapy and TRAIL. The technology has demonstrated in vitro and in vivo efficacy, making it a promising candidate for cancer therapy.
IP Type or Form Factor: Patent Pending; Material; Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Pharmaceutical Engineering; Biotechnology
